

#25/105
GP 3/7/02

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 19, 2002.


Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 C.F.R. § 1.111
Examining Group 1655
Patent Application
Docket No. GEN-T124X
Serial No. 09/416,384

RECEIVED

MAR 04 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jeffrey Fredman, Ph.D.
Art Unit : 1655
Applicants : Marta Blumenfeld, Lydie Bougueret, Ilya Chumakov,
Daniel Cohen, Laurent Essioux
Serial No. : 09/416,384
Filed : October 12, 1999
Confirm. No. : 6101
For : GENES, PROTEINS AND BIALLELIC MARKERS RELATED
TO CENTRAL NERVOUS SYSTEM DISEASE

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

Remarks

Claims 58, 62, and 73-75 are pending in the subject application. The Office Action of November 19, 2001 has set forth a variety of rejections

Rejection under 35 U.S.C. § 101:

The Office Action, dated November 19, 2001, has rejected claims 58, 62, and 73-75 under 35 U.S.C. § 101 for allegedly lacking utility. Specifically, the Office Action alleges that the only taught utilities of the protein (encompassed by the present claims) are to detect the protein, to make